New
HealthMore in Health→
Timing of COVID-19 mRNA Vaccination Around ICI Start and Survival in a Nationwide Cancer Cohort
Key Takeaways
- A nationwide, population-based analysis published in Nature Medicine on 10 September 2026 examines COVID-19 mRNA vaccination around the start of immune checkpoint inhibitor (ICI) therapy in patients with cancer.
- The abstract summary states that both pre-ICI and post-ICI COVID-19 mRNA vaccinations were associated with outcomes detailed in the full paper.
- The study design uses the ICI start date to compare vaccination before versus after treatment initiation, drawing on linked population-level data.
- Observational cohorts of this kind broaden evidence for immunocompromised patients but carry caveats such as confounding by indication and immortal time bias.
DE
DT Editorial Team··via nature.com